New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy

References

• WHO. Global Database on Body Mass Index. Available at: http://apps.who.int/bmi/index.jsp [Last accessed 12 June 2013]
   Google Scholar
• Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity in the United States, 2009–2010. NCHS data brief 1–8 (2012). Available at: http://www.ncbi.nlm.nih.gov/pubmed/22617494 [Last accessed 12 June 2013]
   Google Scholar
• Adan RaH, Vanderschuren LJMJ, La Fleur SE. Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci 2008;29:208-17
   PubMed Web of Science ®Google Scholar
• Ritter RC. Gastrointestinal mechanisms of satiation for food. Physiol Behav 2004;81:249-73
   PubMed Web of Science ®Google Scholar
• Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:714-19
   Web of Science ®Google Scholar
• Schwartz MW, Woods SC, Porte D Jr, et al. Control of food intake. Nature 2000;404:661-72
   PubMed Web of Science ®Google Scholar
• Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature 2006;443:289-95
   PubMed Web of Science ®Google Scholar
• Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Investig 2007;117:13-23
   PubMed Web of Science ®Google Scholar
• Maggi CA. The pharmacology of the efferent function of sensory nerves. J Auton Pharmacol 1991;11:173-208
   PubMedGoogle Scholar
• Jänig W, Morrison JF. Functional properties of spinal visceral afferents supplying abdominal and pelvic organs, with special emphasis on visceral nociception. Progr Brain Res 1986;67:87-114
   PubMed Web of Science ®Google Scholar
• Langley, K. The neuroendocrine concept today. Ann NY Acad Sci 1994;733:1-17
   PubMed Web of Science ®Google Scholar
• Konturek SJ, Konturek JW, Pawlik T, et al. Brain–gut axis and its role in the control of food intake. J Physiol Pharmacol 2004;55:137-54
   PubMed Web of Science ®Google Scholar
• Sargent BJ, Moore N. New central targets for the treatment of obesity. Br J Clin Pharmacol 2009;68:852-60
   PubMed Web of Science ®Google Scholar
• Elias CF, Lee C, Kelly J, et al. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 1998;21:1375-85
   PubMed Web of Science ®Google Scholar
• Hahn TM, Breininger JF, Baskin DG, et al. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998;1:271-2
   PubMed Web of Science ®Google Scholar
• Broberger C, Johansen J, Johansson C, et al. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 1998;95:15043-8
   PubMed Web of Science ®Google Scholar
• Fan W, Boston B, Kesterson R, et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997;385:165-8
   PubMed Web of Science ®Google Scholar
• Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006;89:71-84
   PubMed Web of Science ®Google Scholar
• Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004;145:2607-12
   PubMed Web of Science ®Google Scholar
• Farooqi I, O’Rahilly S. Genetic factors for human obesity. Obes Rev 2007;8:37-40
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Baskin DG, Bukowski TR, et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996;45:531-5
   PubMed Web of Science ®Google Scholar
• Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995;377:530-4
   PubMed Web of Science ®Google Scholar
• Stellar E. The physiology of motivation. Psychol Rev 1954;61:5-22
   PubMed Web of Science ®Google Scholar
• Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008;149:1323-8
   PubMed Web of Science ®Google Scholar
• Nonogak K, Ohashi-Nozue K, Oka Y. A negative feedback system between brain serotonin systems and plasma active ghrelin levels in mice. Biochem Biophys Res Comm 2006;341:703-7
   PubMed Web of Science ®Google Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85
   PubMed Web of Science ®Google Scholar
• Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 1999;96:10911-16
   PubMed Web of Science ®Google Scholar
• Young WS, Kuhar MJ. Noradrenergic alpha 1 and alpha 2 receptors: light microscopic autoradiographic localization. Proc Natl Acad Sci USA 1980;77:1696-700
   PubMed Web of Science ®Google Scholar
• Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 1983;63:844-914
   PubMed Web of Science ®Google Scholar
• Wellman PJ, Davies BT, Morien A, et al. Modulation of feeding by hypothalamic paraventricular nucleus alpha 1- and alpha 2-adrenergic receptors. Life Sciences 1993;53:669-79
   PubMed Web of Science ®Google Scholar
• Jackson HC, Bearham MC, Hutchins LJ, et al. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997;121:1613-18
   PubMed Web of Science ®Google Scholar
• Verhagen JV, Engelen L. The neurocognitive bases of human multimodal food perception: sensory integration. Neurosci Biobehav Rev 2006;30:613-50
   PubMed Web of Science ®Google Scholar
• Wallace MT, Wilkinson LK, Stein BE. Representation and integration of multiple sensory inputs in primate superior colliculus. J Neurophysiol 1996;76:1246-66
   PubMed Web of Science ®Google Scholar
• Savic I, Gulyas B. PET shows that odors are processed both ipsilaterally and contralaterally to the stimulated nostril. Neuroreport 2000;11:2861-6
   PubMed Web of Science ®Google Scholar
• Savic I, Gulyas B, Larsson M, Roland P. Olfactory functions are mediated by parallel and hierarchical processing. Neuron 2000;26:735-45
   PubMed Web of Science ®Google Scholar
• Cerf-Ducastel B, Van de Moortele PF, MacLeod P, et al. Interaction of gustatory and lingual somatosensory perceptions at the cortical level in the human: a functional magnetic resonance imaging study. Chem Senses 2001;26:371-83
   PubMed Web of Science ®Google Scholar
• Poellinger A, Thomas R, Lio P, et al. Activation and habituation in olfaction – an fMRI study. NeuroImage 2001;13:547-60
   PubMed Web of Science ®Google Scholar
• Dallman MF, Pecoraro N, Akana SF, et al. Chronic stress and obesity: a new view of ‘comfort food’. Proc Natl Acad Sci USA 2003;100:11696-701
   PubMed Web of Science ®Google Scholar
• Kelley AE, Baldo BA, Pratt WE, et al. Corticostriatal–hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav 2005;86:773-95
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wise RA. How can drug addiction help us understand obesity? Nat Neurosci 2005;8:555-60
   PubMed Web of Science ®Google Scholar
• Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 2002;22:3306-11
   PubMed Web of Science ®Google Scholar
• Holland PC, Gallagher M. Amygdala–frontal interactions and reward expectancy. Curr Opin Neurobiol 2004;14:148-55
   PubMed Web of Science ®Google Scholar
• Schoenbaum G, Roesch M. Orbitofrontal cortex, associative learning, and expectancies. Neuron 2005;47:633-6
   PubMed Web of Science ®Google Scholar
• Shi C, Cassell MD. Cortical, thalamic and amygdaloid connections of the anterior and posterior insular cortices. J Comp Neurol 1998;468:440-68
   Google Scholar
• Berendse HW, Galis-de Graaf Y, Groenewegen HJ. Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J Comp Neurol 1992;316:314-47
   PubMed Web of Science ®Google Scholar
• Saper CB. The central autonomic nervous system: conscious visceral perception and autonomic pattern generation. Annu Rev Neurosci 2002;25:433-69
   PubMed Web of Science ®Google Scholar
• Swanson LW. Cerebral hemisphere regulation of motivated behavior. Brain Res 2000;886:113-64
   PubMed Web of Science ®Google Scholar
• FDA, Services, U. D. of H. and H. & CDER. Guidance for Industry Developing Products for Weight Management. Available at: www.fda.gov/downloads/Drugs/guidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf [Last accessed 12 June 2013]
   Google Scholar
• Colman E, Golden J, Roberts M, et al. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med 2012;367:1577-9
   PubMed Web of Science ®Google Scholar
• Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol 2009;587:49-60
   PubMed Web of Science ®Google Scholar
• Levine L, Rosenblatt S, Bosomworth J. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int J Obes 1987;11:185-90
   PubMed Web of Science ®Google Scholar
• Heal D, Cheetham S, Prow M, et al. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Clin Pharmacol 1998;125:301-8
   Web of Science ®Google Scholar
• Breisch S, Zemlan F, Hoebel B. Hyperphagia and obesity following serotonin depletion by intraventricular p-chlorophenylalanine. Science 1976;192:382-5
   PubMed Web of Science ®Google Scholar
• Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Therapeut 2008;325:577-87
   PubMed Web of Science ®Google Scholar
• Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for ‘sick fat’ and metabolic disease. Expet Rev Cardiovasc Ther 2009;7:1429-45
   PubMedGoogle Scholar
• Halford JCG, Harrold JA, Boyland EJ, et al. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007;67:27-55
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expet Opin Drug Saf 2012;11:459-71
   PubMed Web of Science ®Google Scholar
• Smith S, Prosser W, Donahue D, et al. APD356-004 study group. Lorcaserin (APD356), a selective 5-HT2C agonist, safely induces weight loss in a 12-week study of healthy obese patients. Presented at: American Diabetes Association 66th Annual Scientific Sessions - Washington June 9-13, 2006
   Google Scholar
• Bays HE. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expet Rev Cardiovasc Ther 2011;9:265-77
   PubMedGoogle Scholar
• Smith SR, Prosser WA, Donahue DJ, et al. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009;17:494-503
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metabol 2011;96:3067-77
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring, MD) 2012;20:1426-36
   PubMed Web of Science ®Google Scholar
• Nigro S, Luon D, Baker L. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Curr Med Res Opin 2013;29:839-48
   PubMed Web of Science ®Google Scholar
• Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013;6:560-7
   Google Scholar
• Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol. 2013; 9:467-78
   Google Scholar
• Maryanoff BE. Sugar sulfamates for seizure control: discovery and development of topiramate, a structurally unique antiepileptic drug. Curr Top Med Chem 2009;9:1049-62
   PubMed Web of Science ®Google Scholar
• Zhang X, Velumian AA, Jones OT, et al. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(Suppl 1):S52-60
   PubMed Web of Science ®Google Scholar
• DeLorenzo RJ, Sombati S, Coulter DA. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 2000;41(Suppl 1):S40-4
   PubMed Web of Science ®Google Scholar
• De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharmaceut Des 2008;14:655-60
   PubMed Web of Science ®Google Scholar
• Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41(Suppl 1):S35-9
   PubMed Web of Science ®Google Scholar
• Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 2003;23:7069-74
   PubMed Web of Science ®Google Scholar
• Curia G, Aracri P, Sancini G, et al. Protein-kinase C-dependent phosphorylation inhibits the effect of the antiepileptic drug topiramate on the persistent fraction of sodium currents. Neuroscience 2004;127(1):63-8
   PubMed Web of Science ®Google Scholar
• Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition (Burbank, Los Angeles County, CA) 2000;16:961-6
   PubMed Web of Science ®Google Scholar
• Richard D, Picard F, Lemieux C, et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metabol Disord 2002;26:344-53
   PubMed Web of Science ®Google Scholar
• Hirsch J, Mackintosh R, Aronne L. The effect of drugs used to treat obesity on the autonomic nervous system. Obes Res 2000;8:227-33
   PubMedGoogle Scholar
• Tremblay A, Chaput JP, Bérubé-Parent S, et al. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 2007;63:123-34
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatr 2007;61:1039-48
   PubMed Web of Science ®Google Scholar
• Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss: a review. Epilepsy Res 2011;95:189-99
   PubMed Web of Science ®Google Scholar
• Li HF, Zou Y, Xia ZZ, et al. Effects of topiramate on weight and metabolism in children with epilepsy. Acta Paediatrica 2009;98:1521-5
   PubMed Web of Science ®Google Scholar
• Alberici A, Borroni B, Manelli F, et al. Topiramate weight loss in migraine patients. J Neurol Sci 2009;278:64-5
   PubMed Web of Science ®Google Scholar
• Narula PK, Rehan HS, Unni KES, et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 2010;118:218-23
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders. CNS Drugs 2008;22:27-47
   PubMed Web of Science ®Google Scholar
• Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expet Opin Emerg Drugs 2008;13:383-92
   PubMed Web of Science ®Google Scholar
• Lynch CJ, Fox H, Hazen SA, et al. Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem J 1995;310:197-202
   PubMed Web of Science ®Google Scholar
• Liazen SA, Waheed A, Sly S. Expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. Faseb J 1996;10:481-90
   PubMed Web of Science ®Google Scholar
• Liang Y, She P, Wang X, et al. The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metabolism 2006;55:1411-19
   PubMed Web of Science ®Google Scholar
• York DA, Singer L, Thomas S, et al. Effect of topiramate on body weight and body composition of Osborne–Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000;16:967-75
   PubMed Web of Science ®Google Scholar
• Balcioglu A, Wurtman RJ. Effects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study. Int J Obes Relat Metabol Disord 1998;22:325-8
   PubMed Web of Science ®Google Scholar
• Hoebel B, Hernandez L, Schwartz D, et al. Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior theoretical and clinical implications. Ann NY Acad Sci 1989;575:171-93
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-52
   PubMed Web of Science ®Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring, MD) 2012;20:330-42
   PubMed Web of Science ®Google Scholar
• Cameron F, Whiteside G, McKeage K. Phentermine and topiramate extended release (Qsymia): first global approval. Drugs 2012;72:2033-42
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study 1–3. Am J Clin Nutr 2012;95:297-308
   PubMed Web of Science ®Google Scholar
• Shah K, Villareal DT. Combination treatment to CONQUER obesity? Lancet 2011;377:1295-7
   PubMed Web of Science ®Google Scholar
• Ryan DH, Peterson C, Troupin B, et al. ECO2009 Hot topic abstracts. Obesity Facts 2010;3:139-46
   Web of Science ®Google Scholar